Metabolic Diseases Archives - Page 2 of 3

Innovative R&D Strategies for Peptide Drugs in Obesity Treatment

Introduction: Obesity has emerged as a pressing global public health issue, with its prevalence escalating at an unprecedented rate across...

Severe Hyperglycemia and Hyperlipidemia Alter Tumor Growth and Immune Profiles in Syngeneic Tumor Models

Studies have demonstrated that obesity can promote cancer progression through mechanisms that include chronic low-grade inflammation. Previous research with diet-induced...

Alterations in Energy Metabolism and Lipogenesis in GIPR/GLP-1R Agonist-Treated MASH Mice

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a severe form of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). MASH is a growing public...

Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH

Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes,...

Nephropathy Research Platform

Kidney diseases are complex conditions caused by a variety of factors, including autoimmune diseases, metabolic disorders, infections, drug side effects,...

Women’s Health Platform

Women’s health care is crucial not only for the well-being of individual women but also for the health and prosperity...

Metabolic Disease Services Platform

Metabolic diseases are considered to arise from multiple factors, including genetics, diet, age, and environmental factors, and often affect various...

Toxicology Profile of a Novel GLP-1 Receptor Agonist

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However,...

Discovery of a Specific CKIP-1 Ligand using DEL

Casein kinase 2-interacting protein-1 (CKIP-1) performs a critical negative role in the regulation of bone formation. Accumulated evidence strongly supports...

Knowledge Library